Skip to main content
OpenTrials
Completed

NCT Number: NCT01213264

Observational Study to Evaluate the Current Neuromuscular Monitoring Practice Used After Different Types of Surgery, for Which Neuromuscular Blocking Agents Were Used, With or Without Blocking Reversal (P06556)

The intent of this observational study is to collect prospective data regarding neuromuscular monitoring practices and extubation standards (Train-Of-Four [TOF] value) during surgery, in countries of Central and Eastern Europe, Middle East and Africa (CEE/EEMEA countries). Secondarily the study will observe, for which surgical procedures neuromuscular blocking agents (NMBAs), and reversal agents to such, are used. This study is a non-interventional clinical trial, and administration of NMBAs, and respective reversal agents, (as well as all drugs used during anesthesia) will be done in accordance with routine anesthesiology practice, and labeling guidelines. Neuromuscular transmission will be monitored according to routine anesthesiology practice by means of acceleromyography. The assignment of the participant to a particular therapeutic strategy is not decided in advance by a trial protocol, but falls within current practice and the prescription of the medicine is clearly separated from the decision to include the patient in the study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neuromuscular Monitoring After Administration of Neuromuscular Blocking Agents in Different Types of Surgery Cardiovascular Abnormalities Cardiovascular Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Heart Defects, Congenital Heart Diseases Tetralogy of Fallot

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All of the criteria below must be met for a participant to be eligible for study participation.

The prospective participant:

  • Is an adult, 18 to 65 years-of-age;
  • Is to undergo surgery requiring general anesthesia with non-depolarizing NMBA administration, with or without NMB reversal;
  • Meets the inclusion criteria listed on the NMBA label in each country;
  • Is willing to participate and sign an informed consent form (ICF).

Exclusion criteria

Exclusion from the study will be determined by the treating physician. In addition the criteria below should be considered in determining those participants who should be excluded from the study.

The prospective participant:

  • Is pregnant or breast feeding;
  • Has a neuromuscular disorder;
  • Has severe hepatic impairment;
  • Has severe renal impairment.

Treatment and study plan

No neuromuscular blockade (NMB)-reversal agent used

Other

Participants whose reversal from NMB is spontaneous (no reversal agent used)

Sugammadex

Drug

Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.

As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive the NMB-reversal agent sugammadex, administered according to the local clinical practice and drug product labeling.

Other names: Bridion, SCH 900616

Other NMB-Reversal Agents Used in Routine Anesthesiology Practice

Drug

Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.

As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive any NMB-reversal agent other than sugammadex, and represents multiple drugs whose use and administration may vary according to local clinical practice, product availability and product labeling.

Primary outcomes

  1. Number of Participants With a Train-Of-Four (TOF)-Ratio <0.9 at Extubation

    Time frame: At extubation (approximately <1 to 125 minutes after end of surgery)

    Neuromuscular function assessment was performed according to routine anesthesiology practice. This typically involves application of repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve and assessment of twitch response at the adductor pollicis muscle. The TOF-ratio, expressed as a decimal from 0.0 up to 1.0, is the ratio of the magnitude of the fourth twitch (T4) to that of the first twitch (T1). The greater the T4/T1 ratio the greater the recovery from neuromuscular blockade. The TOF-ratio was measured at the time of post-surgical extubation. TOF-ratio at time of extubation was to be recorded for each participant, if available, irrespective of the criteria used to make the decision to extubate the participant. TOF-ratio <0.9 at extubation is considered to indicate a high risk for development of postoperative residual curarization (i.e, residual neuromuscular blockade), which can result in respiratory complications.

  2. Time From End of Surgery (End of Last Stitch) to Extubation

    Time frame: From end of surgery (end of last stitch) to extubation (duration of approximately <1 to 62 minutes)

    This measure is the duration from the last surgical wound stitch to the post-surgical extubation of the participant. The time of extubation was to be recorded for each participant, irrespective of the criteria used to make the decision to extubate the participant. Data are presented by TOF-ratio <0.9 and ≥0.9 at extubation. The TOF-ratio is a measure of neuromuscular function ranging from 0.0 to 1.0. The greater the T4/T1 ratio the greater

    the recovery from neuromuscular blockade. TOF-ratio <0.9 at extubation is considered to indicate a high risk for development of postoperative residual curarization (i.e, residual neuromuscular blockade), which can result in respiratory complications.

  3. Type of Surgical Procedure Performed in Study Participants

    Time frame: Day of surgery (Day 1)

    The type of surgical procedure performed in each study participant was recorded.

  4. Type of NMB-reversal Agent Administered to Study Participants

    Time frame: At administration of NMB-reversal agent (up to approximately 395 minutes after start of surgery)

    For all participants who received an NMB-reversal agent, the specific agent administered was recorded.

Secondary outcomes

  1. Time From NMB-reversal Agent Administration to Operating Room Dismissal

    Time frame: Post-surgical period (up to approximately 24 hours post-surgery)

    This measure is the duration from NMB-reversal agent administration to dismissal of the participant from the Operating Room. The time of dismissal from the Operating Room was to be recorded for each participant, irrespective of the criteria used to make the decision to dismiss the participant.

  2. Time From NMB-reversal Agent Administration to Recovery Room Dismissal

    Time frame: Post-surgical and recovery period (up to approximately 170 hours post-surgery)

    This measure is the duration from NMB-reversal agent administration to dismissal of the participant from the Recovery Room. The time of dismissal from the Recovery Room was to be recorded for each participant, irrespective of the criteria used to make the decision to dismiss the participant.

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

Observational Project on the Current Neuromuscular Monitoring Practice (Including Extubation Practice) Via TOF-ratio (Train-of-four) Measurements in Different Types of Surgery After Administration of Neuromuscular Blocking Agents With or Without Reversal (Protocol No. P06556)

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Oct 1, 2010
Registry last updated
Mar 17, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.